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Introduction
Some of the best ideas in clinical medicine are simple
ones, and SLN biopsy is one of these. The hypothesis that
one or a few lymph nodes receive the first drainage from a
tumor site, and that a regional node dissection and its
morbidity might be avoided if the SLNs prove negative, is
logical and intuitive. First suggested by Cabanas [1] in the
context of penile cancer and conceived in its modern form
in a 1992 report by Morton et al [2], SLN biopsy is rapidly
emerging as a new standard of care in melanoma and
breast cancer. The procedure has promise but remains
investigational in patients with head and neck, urologic,
gynecologic, and colorectal cancers. SLN biopsy’s imme-
diate potential is greatest among patients with breast
cancer, by far the most significant group numerically, and
will be the focus of this overview. Among an estimated
184,200 new cases of breast cancer in the United States
last year [3], about 60% (110,000) had disease limited to
the breast and might have avoided a conventional axillary
lymph node dissection (ALND) through SLN biopsy.
By the end of 1999, 41 peer-reviewed pilot studies using
radioisotope [4–19] or blue dye [20–30] methods, or a
combination of both [31–42] (Table 1), report the results of
SLN biopsy validated by a ‘backup’ ALND in breast cancer
patients. SLNs were identified in 90% of cases, correctly
identified 93% of axillary node-positive individuals, and
were the only site of nodal metastasis in 47% of these. An
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Abstract
Sentinel lymph node (SLN) biopsy requires validation by a backup axillary dissection in a defined
series of cases before becoming standard practice, to establish individual and institutional success
rates and the frequency of false negative results. At least 90% success in finding the SLN with no
more than 5–10% false negative results is a reasonable goal for surgeons and institutions learning
the technique. A combination of isotope and dye to map the SLN is probably superior to either
method used alone, yet a wide variety of technical variations in the procedure have produced a
striking similarity of results. Most breast cancer patients are suitable for SLN biopsy, and the large
majority reported to date has had clinical stage T1-2N0 invasive breast cancers. SLN biopsy will play
a growing role in patients having prophylactic mastectomy, and in those with ‘high-risk’ duct
carcinoma  in situ, microinvasive cancers, T3 disease, and neoadjuvant chemotherapy. SLN biopsy for
the first time makes enhanced pathologic analysis of lymph nodes logistically feasible, at once
allowing greater staging accuracy and less morbidity than standard methods. Retrospective data
suggest that micrometastases identified in this way are prognostically significant, and prospective
clinical trials now accruing promise a definitive answer to this issue.
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increasing number of centers, having completed validation
studies of SLN biopsy, offer patients the option of no
further axillary surgery if the SLN is negative. Despite this
encouraging debut, SLN biopsy is a new operation, has a
definite learning curve, and is highly multidisciplinary,
requiring the cooperation of nuclear medicine physicians,
surgeons, and pathologists. The techniques pertinent to
each specialty continue to evolve, and many of these
aspects remain the subject of debate. We have performed
more than 3000 SLN biopsy procedures since 1996, and
the following represents a distillation of our experience,
recently reviewed in detail [43], and that of other workers.
Protocol design and learning curve issues
The benefit of SLN biopsy seems clear, but the technique
is a new one, the long term consequences are not fully
defined, and the medicolegal risks are unknown. Institu-
tions beginning to perform this procedure should do so
under a formalized Institutional Review Board protocol, in
which selection and technique are carefully specified,
patients are fully informed, a backup axillary dissection is
carried out to validate the early experience, and careful
audits of individual and institutional results (short and long
term) are maintained. A success of 90–95% in finding the
SLN and no more than 5–10% false negative results
would seem reasonable targets for validation trials.
We have found that success in localizing the SLN contin-
ued to improve over our first 500 cases, and that one-half
of our false negative results occurred within the first six
cases of each surgeon [44]. Cox et al [45] found that, to
identify the SLN, surgeons required an average of 23
cases to achieve 90% success and 53 cases to achieve
95% success, although the SLN was falsely negative in
only 2% of their node-positive patients [39]. While most
authorities recommend that each surgeon initially perform
20–30 SLN procedures with a backup ALND, fewer vali-
dated cases may be necessary. McMasters et al [46], in a
remarkable multi-institutional trial involving 806 patients
and 99 surgeons, found that the frequency of successful
mapping and of false negative results was identical
whether the participating surgeons had prior experience of
more than or fewer than 10 SLN operations.
SLN may be identified by either radioisotope or blue dye
methods and, while each technique by itself enjoys the
vocal support of a few investigators [10,21], an emerging
international consensus (and our own experience
[33,47,48]) supports the use of both methods in combi-
nation. We continue to find that about 10% of SLN, and
10% of positive SLN, are found by either dye or isotope
alone, and presumably would have been missed by
reliance on a single method. McMasters et al [46]
demonstrate that false negatives occur half as often with
a combined technique as with a single-agent SLN
mapping technique.
Case selection
Most of the reported experience with SLN biopsy
includes patients with clinical stage T1-2N0 invasive
breast cancers. SLN biopsy has an emerging role in
microinvasive cancers and in selected cases of duct car-
cinoma  in situ, particularly those with a high risk of
occult invasion (evidenced by a palpable mass or exten-
sive disease requiring mastectomy). While neither group
is normally considered for a conventional ALND, about
10% of microinvasive or high-risk duct carcinoma in situ
patients harbor micrometastases in their SLN [49]. SLN
biopsy is reasonable at the time of a prophylactic mas-
tectomy, to avoid the need for reoperative ALND if inva-
sive cancer is unexpectedly found in the breast (as is the
case in perhaps 5% of prophylactic mastectomies). SLN
biopsy works well for nonpalpable cancers requiring
needle localization [50], and in the setting of a prior sur-
gical biopsy [47]. While equally accurate for T1 and T2
cancers [51,52], high false negative rates occur in T3
cancers and in patients with surgical disruption of the
axillary lymphatics by a large upper outer quadrant
biopsy cavity. Diagnosis should, for this reason, be by
fine-needle aspiration (FNA) or core needle biopsy
whenever possible. Even in the setting of advanced
disease, SLN biopsy may play a role in estimating
response to neoadjuvant chemotherapy [53]. Finally,
SLN biopsy is reasonable in selected patients with clini-
cally palpable axillary nodes thought to be reactive, as
long as the surgeon maintains a low threshold for default
to conventional ALND.
Table 1
Cumulative results of sentinel lymph node (SLN) biopsy, 1993–1999
Method SLN found False negative SLN Accuracy overall
Isotope [4–19] 2112/2292 (92%) 54/779 (7%) 1942/1996 (97%)
Blue dye [20–30] 714/886 (81%) 23/245 ((9%) 691/717 (96%)
Combined [31–42] 1071/1155 (93%) 21/417 (5%) 1042/1063 (98%)
Total 3897/4333 (90%) 98/1441 (7%) 3675/3776 (97%)
Data presented as n (%). False negative SLN, (false negative SLN)/(true positive axilla); accuracy overall, (true positive SLN + true negative SLN)/
(total cases in which SLN was found).Breast Cancer Research    Vol 3 No 2 Cody
Nuclear medicine aspects
Overall, radioisotope mapping of the SLN succeeds more
often than blue dye (92% versus 81%; Table 1). Intuition
would suggest that tracer injection into or directly adjacent
to the tumor would most accurately identify the SLN. A
number of studies, however, have found that SLN identified
by intraparenchymal, ‘subdermal’, intradermal or subareolar
injections [18,28,32,54,55] stage the axilla with compara-
ble accuracy, and that the entire breast and its overlying
skin function as a single lymphatic unit in most patients
[56]. This may explain why such a wide variation in isotope
techniques (dosage of isotope, carrier particle, route/
timing/volume of injection, and definition of a successful
result) produces such a similarity of outcome. We have
achieved optimal success using blue dye injected intra-
parenchymally and unfiltered [57] Tc-99m sulfur colloid in
0.05 cm3 saline injected intradermally [54] into a single site
directly over the tumor, at a dose of 0.1 mCi for same-day
and 0.5 mCi for day-before injection. In our most recent
experience, we have identified the SLN in 97% of cases.
Preoperative lymphoscintigraphy is essential in the man-
agement of melanoma, and can indeed also show unex-
pected patterns of lymphatic drainage (supraclavicular,
internal mammary, Rotter’s node) in about 20% of breast
cancer patients [58]. Because gross recurrence in these
nonaxillary sites is a very rare event in early-stage breast
cancer, the clinical relevance of this finding is uncertain,
and the role of routine preoperative lymphoscintigraphy in
breast cancer patients remains a matter of debate.
Surgical aspects
SLN biopsy is usually a straightforward and simple opera-
tion [43]. Before the procedure on the breast (excision or
mastectomy), blue dye is injected into the breast just super-
olateral to the tumor (or biopsy) site, and isotope counts are
taken from the axilla and the injection site in the breast using
a hand-held gamma probe. An axillary incision is made, and
the surgeon identifies and removes the SLN by looking for
blue-stained lymphatic vessels or nodes and using the
gamma probe to identify focally ‘hot’ nodes. All blue and/or
hot nodes are removed until the axillary background counts
fall below a threshold value; most authors report a median
of two SLN per patient. Once the surgeon has passed the
validation phase in which backup ALND is performed rou-
tinely, the SLN are submitted for frozen section and either
tumor excision or mastectomy is performed while waiting for
the pathologists’s report. ALND is performed if the SLNs
contain tumor or if there are clinically suspicious nonSLNs
palpable at the time of surgery. Clinically suspicious
nonSLNs were present in more than one-half of our false
negative SLN biopsy procedures [43,47], suggesting that
gross tumor involvement of the nodes may impair the uptake
of both isotope and dye by the ‘true’ SLN. Careful intraoper-
ative palpation of the axilla is an essential component of
SLN biopsy, and the surgeon facing suspicious findings
should not hesitate in defaulting to ALND.
Pathologic aspects
Frozen section analysis of the SLN, if positive, allows an
immediate ALND, sparing the patient a reoperation. While
limited in its ability to detect micrometastases (which pre-
dominate in the smallest invasive cancers), the frozen
section of the SLN demonstrates sensitivity ranging from
40% for T1a to 60% for T2 cancers [59].
Lymph nodes in ALND specimens are normally examined
by a single hematoxylin and eosin stained section. When
nodes found to be negative by this standard method are
further studied with serial sectioning and immunohisto-
chemical stains for cytokeratins, missed metastases are
found in 10–20% of cases [60]. The overwhelming major-
ity of studies with adequate statistical power demonstrate
that these missed metastases are prognostically signifi-
cant, associated with a 10–15% worsening of disease-
free survival [60–62]. SLN biopsy for the first time makes
enhanced pathologic analysis logistically feasible, and
allows the identification of a group of patients whose
increased risk of systemic relapse might otherwise go
unrecognized. While SLN biopsy is itself subject to a small
percentage of false negative results, the proportion of
false negatives with a conventional pathologic analysis of
the axillary nodes is perhaps 10-fold greater.
A striking parallel to the presented findings arises from
two German studies [63,64], in which the bone marrow of
breast cancer patients harvested at the time of their
surgery was examined for micrometastases using immuno-
histochemical staining. Both demonstrate, firstly, a strong
correlation of micrometastases with stage of disease and,
secondly, an ‘independent’ prognostic significance of
bone marrow micrometastases that equals or exceeds that
of axillary node status.
Breast cancer is a disease characterized by heterogeneity,
and nowhere is this heterogeneity more apparent than at
the level of the SLN. Enhanced pathologic analysis using
immunohistochemical and serial sections may identify SLN
containing single metastatic cells, tiny groups of cells,
micrometastatic clusters, or even large macrometastases
found on a directed retrospective review of the hematoxylin
and eosin stained sections. These gradations suggest that
not all nodal metastases are the same, but they rather rep-
resent a spectrum of risk, posing a dilemma for the oncolo-
gist trying to ascertain the necessity of systemic adjuvant
treatment. Even with the maturity of clinical trials now in
progress, the prognostic significance of occult SLN metas-
tases will remain a matter of controversy.
Follow-up
The follow-up of patients after SLN biopsy, as for breast
cancer patients in general, is for life. While local recur-
rence has been reported in the regional node basin after
SLN biopsy for melanoma [65], no such recurrences havebeen observed in breast cancer patients after a negative
SLN biopsy, either in our experience or that of others [66].
Such recurrences will recur, but we ultimately expect that
that the rate of isolated axillary relapse after a negative
SLN biopsy will be comparable with that after a conven-
tional axillary dissection, 1% or less. We expect the other
long term morbidities of SLN biopsy to also be substan-
tially less than that of axillary dissection, if not zero. Early
results from a prospective study of our own patients
demonstrate a substantial reduction in postoperative
sensory phenomena for SLN biopsy compared with axillary
dissection; long term studies also address the relative risk
of lymphedema and cellulitis.
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